Vivani Q2 net loss $6.4M; SLIM-1 fully enrolled; Novo Nordisk deal; Cortigent merger on track

Vivani Medical, Inc.

2026-Q2 EPS reported -$0.16

Q2 2026 net loss $6.4M vs $7.1M in Q2 2025; cash $20.8M at June 30, 2026.
SLIM-1 Phase 1 trial of NPM-139 fully enrolled (20 participants); top-line data expected November 2026.
Non-exclusive agreement with Novo Nordisk to evaluate NPM-139 semaglutide implant; no exclusivity provisions.
Cortigent merger with ClearOne expected to close Q3 2026; post-merger company to trade as CRGT on Nasdaq.
August J. Moretti appointed to board; former CFO of 4D Molecular Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.